-
Fucoidan: Protocol Advances for Anticancer Polysaccharide Re
2026-05-22
APExBIO's Fucoidan enables robust, targeted workflows for oncology and immunology research, offering protocol flexibility and unparalleled purity. This guide translates new mechanistic insights into hands-on experimental advantages and troubleshooting strategies.
-
DiscoveryProbe Bioactive Compound Library Plus: Workflows &
2026-05-21
The DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) empowers high-throughput screening and advanced pathway analysis with 5,072 rigorously validated bioactive compounds. This article details optimized workflows, troubleshooting strategies, and experimental enhancements that set this APExBIO library apart for drug discovery and mechanism-of-action studies.
-
DPP9-KEAP1 Complex: Redox Sensing and Inflammasome Regulatio
2026-05-21
This study uncovers a mutually inhibitory interaction between the serine protease DPP9 and the redox sensor KEAP1, directly linking inflammasome regulation to cellular redox homeostasis. The findings provide a new conceptual framework for understanding how redox signals and protease activity converge to modulate innate immune responses, with implications for mitochondrial dysfunction and neurodegenerative disease research.
-
CPI-613 in Tumor Cell Metabolism: Protocols and Optimization
2026-05-20
CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) offers a targeted, reproducible approach for dissecting mitochondrial metabolism and apoptosis in cancer research models. Discover how strategic integration of CPI-613, backed by recent mechanistic studies, streamlines tumor cell assays and advances acute myeloid leukemia and NSCLC workflows.
-
Cell Counting Kit-8 (CCK-8) Plus: Enhanced Tetrazolium Salt
2026-05-20
The Cell Counting Kit-8 (CCK-8) Plus provides rapid and sensitive quantification of living cells, enabling reliable cell proliferation and cytotoxicity assays. It is best suited for in vitro applications requiring precise dehydrogenase activity measurement, but should not be used where endpoint cell lysis or redox interference is unavoidable.
-
Toxicity of Sulfamonomethoxine in Aquatic Organisms: Insight
2026-05-19
This study systematically quantifies the acute and chronic toxicity of the sulfonamide antibiotic sulfamonomethoxine (SMM) across five aquatic species, revealing pronounced sensitivity in microalgae compared to cladocerans and fish. The findings highlight the ecological risks posed by SMM residues in aquatic environments and offer a robust foundation for environmental hazard assessment and buffer optimization in aquatic toxicity assays.
-
Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding
2026-05-19
A recent study reveals that naturally occurring angiotensin peptides, including Angiotensin III, significantly enhance binding of the SARS-CoV-2 spike protein to the host AXL receptor. This work provides mechanistic insight into potential links between the renin–angiotensin–aldosterone system (RAAS) and COVID-19 pathogenesis, with implications for both cardiovascular and infectious disease research.
-
Fucoidan Downregulates Caveolin-1 in MCF-7 Breast Cancer Cel
2026-05-18
This study demonstrates that fucoidan—a sulfated α-L-fucan from brown algae—selectively reduces caveolin-1 expression in MCF-7 breast cancer cells, revealing a novel mechanism for its antitumor activity. The findings suggest caveolin-1 modulation as a promising therapeutic strategy and provide new impetus for translational research on anticancer polysaccharides.
-
Oseltamivir Acid: Influenza Neuraminidase Inhibitor Benchmar
2026-05-18
Oseltamivir acid is a potent influenza neuraminidase inhibitor and active metabolite of oseltamivir phosphate. It directly inhibits viral sialidase activity, interrupting influenza virus replication and spread. Research demonstrates robust in vitro and in vivo efficacy, but resistance via H275Y mutation is a significant limitation.
-
ATM Inhibition with Fenofibrate: Synergy in Ovarian Cancer C
2026-05-17
This study demonstrates that ATM kinase inhibition synergizes with the metabolic drug fenofibrate to induce senescence in high grade serous ovarian cancer (HGSOC) cells. The findings highlight a new combinatorial approach for treating HR-proficient HGSOC, which is often resistant to current therapies.
-
Kaempferol’s Inhibition of Ferroptosis in Vitiligo via NF-κB
2026-05-16
This study uncovers the mechanism by which kaempferol protects human melanocytes from ferroptosis in vitiligo, implicating the NF-κB/PTGS2 signaling axis as a critical mediator. The findings highlight new therapeutic targets for oxidative stress-driven melanocyte loss and offer a mechanistic framework for ferroptosis modulation in depigmenting disorders.
-
Dual Inhibition of FUBP1 and Topoisomerase I by SN-38 in Can
2026-05-15
This study reveals that 7-Ethyl-10-hydroxycamptothecin (SN-38), beyond its established role as a topoisomerase I inhibitor, directly impedes the binding of the oncogenic transcription regulator FUBP1 to its DNA target sequence FUSE. The findings expand the mechanistic understanding of SN-38 and camptothecin analogs, suggesting their dual action could enhance therapeutic strategies in hepatocellular and colorectal cancers.
-
Thioredoxin 1 Regulates Lens Iron Metabolism in Late Oxidati
2026-05-15
This study identifies Thioredoxin 1 (Trx1) as a novel regulator of iron metabolism during the late stage of oxidative damage in lens tissue, a key process in age-related cataract formation. By elucidating the interplay between Trx1, iron homeostasis, and antioxidant defense, the findings provide new targets for mitigating cataract progression.
-
Fludarabine: Redefining Antigen Presentation in Oncology Res
2026-05-14
This article offers translational researchers a mechanistic and strategic exploration of Fludarabine’s dual role as a DNA synthesis inhibitor and a dynamic modulator of tumor immunogenicity. Synthesizing recent mechanistic insights—including evidence of Fludarabine’s impact on antigen presentation and synergy with adoptive cell therapies—this piece delivers actionable guidance for optimizing experimental design in leukemia and multiple myeloma research. The discussion builds on recent landmark findings and positions APExBIO’s Fludarabine as a pivotal tool for modern immuno-oncology workflows, differentiating itself from conventional product-focused content by bridging detailed mechanistic rationale with forward-looking translational strategy.
-
WM-8014: Precision KAT6A Inhibitor for Advanced Cancer Resea
2026-05-14
WM-8014 empowers cancer biology and epigenetic research with unmatched selectivity for KAT6A/B inhibition and minimal cytotoxicity. Its application in oncogene-induced senescence workflows demonstrates reproducible cell cycle arrest, enabling robust mechanistic studies and drug screening. Discover how WM-8014, supplied by APExBIO, optimizes experimental design and data reliability.